Abstract
Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go. © 2009 Wolters Kluwer Health | Lippinoott Williams & Wilkins.
| Original language | English |
|---|---|
| Pages (from-to) | 44-53 |
| Number of pages | 9 |
| Journal | Current Opinion in Obstetrics and Gynecology |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2009 |
Keywords
- Epidermal growth factor receptor inhibitors
- Epithelial ovarian cancer
- Poly-ADP-ribose polymerase inhibitors
- Targeted therapies
- Tyrosine kinase inhibitors
- Vascular endothelial growth factor inhibitors
